Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index.
Rovesti G, Leone F, Brandi G, Cesario S, Scartozzi M, Niger M, Yoo C, Filippi R, Casagrande M, Silvestris N, Santini D, Faloppi L, Palloni A, Aglietta M, Bernardini L, Cho H, Lai E, Fenocchio E, Pircher C, Iacono D, De Lorenzo S, Sperti E, Massa V, De Braud F, Jeong JH, Aprile G, Burgio V, Cascinu S, Casadei-Gardini A. Rovesti G, et al. Among authors: massa v. J Gastrointest Cancer. 2022 Sep;53(3):528-536. doi: 10.1007/s12029-021-00649-3. Epub 2021 May 25. J Gastrointest Cancer. 2022. PMID: 34033000
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib.
Caputo F, Dadduzio V, Tovoli F, Bertolini G, Cabibbo G, Cerma K, Vivaldi C, Faloppi L, Rizzato MD, Piscaglia F, Celsa C, Fornaro L, Marisi G, Conti F, Silvestris N, Silletta M, Lonardi S, Granito A, Stornello C, Massa V, Astara G, Delcuratolo S, Cascinu S, Scartozzi M, Casadei-Gardini A. Caputo F, et al. Among authors: massa v. PLoS One. 2020 May 7;15(5):e0232449. doi: 10.1371/journal.pone.0232449. eCollection 2020. PLoS One. 2020. PMID: 32379785 Free PMC article.
First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age?
Vivaldi C, Salani F, Rovesti G, Pecora I, Catanese S, Casadei-Gardini A, Massa V, Bernardini L, Riggi L, Andrikou K, Rapposelli GI, Formica V, Lencioni M, Falcone A, Vasile E, Fornaro L. Vivaldi C, et al. Among authors: massa v. Eur J Cancer. 2020 Sep;137:108-116. doi: 10.1016/j.ejca.2020.06.031. Epub 2020 Aug 1. Eur J Cancer. 2020. PMID: 32750500
Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis.
Bang Y, Yoo C, Lonardi S, Kim HD, Vivaldi C, Rimini M, Frassineti GL, Park SR, Rizzato MD, Ryu MH, Salani F, Rapposelli IG, Ryoo BY, Zagonel V, Massa V, Valgiusti M, Burgio V, Scartozzi M, Cascinu S, Casadei-Gardini A. Bang Y, et al. Among authors: massa v. Target Oncol. 2021 May;16(3):401-410. doi: 10.1007/s11523-021-00797-3. Epub 2021 Mar 1. Target Oncol. 2021. PMID: 33646487
Correction to: Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis.
Bang Y, Yoo C, Lonardi S, Kim HD, Vivaldi C, Rimini M, Frassineti GL, Park SR, Rizzato MD, Ryu MH, Salani F, Rapposelli IG, Ryoo BY, Zagonel V, Massa V, Valgiusti M, Burgio V, Scartozzi M, Cascinu S, Casadei-Gardini A. Bang Y, et al. Among authors: massa v. Target Oncol. 2021 May;16(3):411-412. doi: 10.1007/s11523-021-00808-3. Target Oncol. 2021. PMID: 33738697 No abstract available.
125 results